Short, multivalent peptide antagonists to block macrophage immune-receptor SIRPα, promoting cancer cell phagocytosis.
A method to combine two or three monoclonal antibodies (mABs) into one treatment to successfully bind to multiple cancer cell surface epitopes and promote targeted degradation by phagocytosis.
A method to streamline the process of generating chimeric antigen receptor (CAR) T cells for therapeutic applications.
CAR-T cells are PEGylated to block the interactions with monocytes and macrophages to reduce the side effects of CAR-T cell therapies (cytokine release syndrome and neurotoxicity).
Using mRNA-LNPs to deliver forkhead box protein 3 (Foxp3) to CD4+ T cells to engineer Foxp3-positive T (FP3T) cells with immunosuppressive properties.
Targeting retinoic acid (RA) synthesizing enzymes or RA receptors with small molecules boosts the immune system towards a tumor rejection response
[%brief%]
A method that maintains the viability and function of NK cells following cryopreservation, enabling the production, storage, and transportation of therapeutic doses of NK cells to treatment centers.
Hydroxycholesterols are used to formulate lipid nanoparticles (LNPs) for enhanced mRNA delivery into T cells.
A dietary supplement that protects brain cells from the effects of TBI and concussion